The global intravenous (IV) hydration therapy market size accounted for USD 2.71 billion in 2024, grew to USD 2.93 billion in 2025 and is predicted to be worth around USD 5.84 billion by 2034, registering a CAGR of 7.98% between 2024 and 2034. The North America intravenous (IV) hydration therapy market size is evaluated at USD 1.27 billion in 2024 and is expected to grow at a CAGR of 8.06% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Intravenous (IV) Hydration Therapy Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Intravenous (IV) Hydration Therapy Market, by Service, 2024-2034
8.1.1 Immune Boosters
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Energy Boosters
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Skin Care
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Migraine
8.1.4.1. Market Revenue and Forecast (2021-2034)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2021-2034)
9.1. Intravenous (IV) Hydration Therapy Market, by Component, 2024-2034
9.1.1. Medicated
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Non-Medicated
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. Intravenous (IV) Hydration Therapy Market, by End-Use, 2024-2034
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Wellness Centers and Spas
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Home Healthcare
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Others
10.1.4.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Service (2021-2034)
11.1.2. Market Revenue and Forecast, by Component (2021-2034)
11.1.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Component (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Component (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.2. Market Revenue and Forecast, by Component (2021-2034)
11.2.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Component (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Component (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Component (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Service (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Component (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.2. Market Revenue and Forecast, by Component (2021-2034)
11.3.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Component (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Component (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Component (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Service (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Component (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.2. Market Revenue and Forecast, by Component (2021-2034)
11.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Component (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Component (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Component (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Service (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Component (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.5.2. Market Revenue and Forecast, by Component (2021-2034)
11.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Service (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Component (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End-Use (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Service (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Component (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End-Use (2021-2034)
12.1. Core IV Therapy, LLC
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Otsuka Pharmaceutical Co., Ltd.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Baxter International Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Drip Hydration
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. NexGen Health
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. JW Life Science Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Amanta Healthcare
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Cryojuvenate UK Ltd.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. B. Braun Medical Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample